LSCP Laserscope (MM)

Laserscope Introduces Enhanced GreenLight(TM) Laser System at 2005 American Urological Association (AUA) Annual Meeting Abstracts Presented at Meeting Demonstrate Continued High Safety and Efficacy Profile of Laserscope's PVP Treatment for Enlarged Prostate SAN JOSE, Calif., May 23 /PRNewswire-FirstCall/ -- Laserscope (NASDAQ:LSCP), a pioneer in the development and commercialization of medical lasers and advanced fiber-optic devices, today announced that it has introduced an enhanced version of its revolutionary GreenLight(TM) laser system for Photoselective Vaporization of the Prostate (PVP) at the 100th American Urological Association Annual Meeting. The meeting is currently taking place until May 26, 2005 at the Henry B. Gonzalez Convention Center in San Antonio, Texas. GreenLight(TM) Laser System Re-engineered The improved GreenLight laser system has been re-engineered and integrated with new fiber-optic delivery device enhancements to provide physicians with even better performance through maximum fiber flexibility and control. Increased system up-time, faster new site set-up time and "real-time" response to fiber manipulation are just a few of the important features of the enhanced GreenLight laser and the integrated fiber-optic delivery device. Laserscope will begin shipping the improved version of the system and delivery device immediately to new customers and plans to make the new features available to its current installed base through an upgrade program. Medical Abstracts Confirm Benefits of PVP The 2005 AUA Annual Meeting will feature the presentation of 10 studies related to Laserscope's PVP procedure, including two randomized trials comparing PVP and Trans Urethral Resection of the Prostate (TURP), the surgical 'gold standard' for Benign Prostatic Hyperplasia ("BPH"), or enlarged prostate. The randomized studies mark a significant milestone because they independently affirm that PVP delivers comparable clinical outcomes with substantially lower risks and complications, and shorter recovery times. All of the presented abstracts, which were written by prominent researchers and physicians from around the world, once again confirm the significant benefits of PVP using the GreenLight laser system over other forms of BPH treatments and demonstrate: * Improved healthcare costs through utilization of the PVP procedure; * Substantial improvement in safety over TURP, while providing equivalent efficacy; and * The safety and effectiveness of PVP for a wide variety of patients including those with special needs such as those who are fragile, those with large prostate glands and those being treated with blood thinning medication for other ailments. For a complete list of the PVP-related abstracts being presented at the 2005 AUA annual meeting please visit Laserscope's website (http://www.laserscope.com/) and click on "Urology." "We are very excited to have such a significant presence at this year's AUA annual meeting," said Eric Reuter, President and Chief Executive Officer of Laserscope. "Our improved GreenLight laser system and delivery device should be a highlight of the meeting, as the enhancements improve system performance, making treatment of BPH even easier. "The number of abstracts being presented at this year's meeting about our PVP procedure is much higher than at any past conference, indicating a growing interest in PVP as a preferable alternative to many other forms of BPH treatment. In fact, we believe this year's presentations continue to show that PVP is quickly becoming the de facto standard of care for the treatment of BPH. The outpatient nature of the procedure, combined with a well-demonstrated safety and efficacy profile, is propelling PVP toward the number one position as the treatment of choice for the many men around the world exhibiting symptoms of BPH." About Laserscope Laserscope designs, manufactures, sells and services on a worldwide basis an advanced line of medical laser systems and related energy delivery devices for the office, outpatient surgical center, and hospital markets. For more information about the Company, please visit Lasercope's booth #1272 at the 2005 AUA Annual Meeting or visit the Company's web site at http://www.laserscope.com/. Safe Harbor Statement Except for historical information presented, the matters discussed in this press release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected. These forward-looking statements include: statements about Laserscope's competition, and expected continued momentum of Laserscope's business and growth, worldwide adoption rates of the PVP procedure using our GreenLight(TM) laser system. These statements are subject to a number of risks and uncertainties, including: uncertainties regarding introduction of new technologies competitive to our products and the degree to which our current and new products are accepted by customers, which could affect the level of demand for our products; risk of reductions in government and private insurance reimbursement of hospitals and physicians for health care costs, which may negatively impact hospitals and physicians decisions to purchase our products reducing adoption rates and sales growth; risks that we may be unable to protect adequately the integrity, safety and proper use of our disposable fiber-optic delivery device with the GreenLight laser system, which could result in negative patient outcomes and reduce our disposable fiber recurring revenue stream; and uncertainties that new products will receive regulatory approval in applicable jurisdictions. These and other risks are detailed from time to time in the Company's public disclosure filings with the U.S. Securities and Exchange Commission (SEC). Copies of Laserscope's public disclosure filings with the SEC, including the most recent Annual Report on Form 10-K and the most recent Forms 10-Q are available upon request from its Investor Relations Department, at the Company's web site at http://www.laserscope.com/ or at the SEC's website at http://www.sec.gov/. Laserscope assumes no obligation to update the forward-looking information contained in this press release. At Laserscope: Eric Reuter, President & CEO Dennis LaLumandiere, CFO (408) 943-0636 At Financial Relations Board: Tricia Ross, Analyst Contact (617) 520-7064 Laurie Berman, General Inquiries (310) 854-8315 DATASOURCE: Laserscope CONTACT: Eric Reuter, President & CEO, or Dennis LaLumandiere, CFO, both of Laserscope, +1-408-943-0636; or analysts, Tricia Ross, +1-617-520-7064, or general inquiries, Laurie Berman, +1-310-854-8315, both of Financial Relations Board, for Laserscope Web site: http://www.laserscope.com/

Copyright